A5047514488- Sarcoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Advanced Radiotherapy Techniques
- Brain Metastases and Treatment
- Cardiac tumors and thrombi
- Management of metastatic bone disease
- Bone Tumor Diagnosis and Treatments
- Radiation Therapy and Dosimetry
- Medical Imaging Techniques and Applications
- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Hedgehog Signaling Pathway Studies
- Meningioma and schwannoma management
- Breast Cancer Treatment Studies
- Gastrointestinal Tumor Research and Treatment
- Neurofibromatosis and Schwannoma Cases
- Musculoskeletal synovial abnormalities and treatments
- Advanced MRI Techniques and Applications
- Tumors and Oncological Cases
- Lung Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Ocular Oncology and Treatments
- Breast Lesions and Carcinomas
- Lung Cancer Research Studies
Centre Léon Bérard
2016-2025
Centre de Recherche en Cancérologie de Lyon
2006-2022
Hospices Civils de Lyon
2021
Université Claude Bernard Lyon 1
2010-2019
Association des Neuro-Oncologues d’Expression Française
2016
Institut d’Hématologie et d’Oncologie Pédiatrique
2010
Institut Bergonié
2007
Institut Claudius Regaud
2007
Centre Oscar Lambret
2007
Centre Eugène Marquis
2007
Well-designed observational studies of individuals with rare tumors are needed to improve patient care, clinical investigations, and the education healthcare professionals.The patterns outcomes, prognostic factors a cohort 2225 patients metastatic soft tissue sarcomas who were diagnosed between 1990 2013 documented in prospectively maintained database French Sarcoma Group analyzed.The median number systemic treatments was 3 (range, 1-6); 27% did not receive any treatment 1054 (49%) underwent...
Preclinical data about the synergistic activity of radiotherapy (RT) and trabectedin have been reported. The combination RT in treating myxoid liposarcomas appears worth exploring.
Abstract Background Glioblastoma (GBM) systematically recurs after a standard 60 Gy radio-chemotherapy regimen. Since magnetic resonance spectroscopic imaging (MRSI) has been shown to predict the site of relapse, we analyzed effect MRSI-guided dose escalation on overall survival (OS) patients with newly diagnosed GBM. Methods In this multicentric prospective phase III trial, who had undergone biopsy or surgery for GBM were randomly assigned (SD) high (HD) an additional simultaneous...
Glioblastoma, a high-grade glial infiltrating tumor, is the most frequent malignant brain tumor in adults and carries dismal prognosis. External beam radiotherapy (EBRT) increases overall survival but this still low due to local relapses, mostly occurring irradiation field. As ratio of spectra choline/N acetyl aspartate> 2 (CNR2) on MR spectroscopic imaging has been described as predictive for site relapse, we hypothesized that dose escalation these regions would increase control hence...
Active therapeutic combinations, such as trabectedin and radiotherapy, offer potentially higher dimensional response in second-line treatment of advanced soft-tissue sarcomas. Dimensional can be relevant both for symptom relief survival.To assess the combined use radiotherapy treating patients with progressing metastatic sarcomas.Phase 1 this nonrandomized clinical trial followed classic 3 + design, planned at a fixed dose 30 Gy (3 Gy/d 10 days) infusion 1.3 mg/m2 starting dose, 1.5 level...
Abstract Background Hypofractionated stereotactic radiotherapy (HFSRT) is indicated for large brain metastases (BM) or proximity to critical organs (brainstem, chiasm, optic nerves, hippocampus). The primary aim of this study was assess factors influencing BM local control after HFSRT. Then the effect surgery plus HFSRT compared with exclusive on oncologic outcomes, including overall survival. Materials and methods Retrospective conducted in Léon Bérard Cancer Center, included patients over...
Act.In.Sarc (NCT02379845) demonstrated that the first-in-class radioenhancer NBTXR3, activated by preoperative radiation therapy (RT), doubled rate of pathologic complete response after resection compared with RT alone in adult patients locally advanced soft tissue sarcoma extremity or trunk wall (16.1% vs 7.9%, P = .045), and more achieved R0 resections (77.0% 64.0%, .042). These are toxicity health-related quality life (HRQoL) results.Act.In.Sarc randomized eligible 1:1 to either NBTXR3...
Abstract Background: Radio-chemotherapy remains the mainstay of glioblastoma first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve outcomes. We implemented a phase 1-2a trial to assess safety and efficacy combined with standard radio-chemotherapy as in unresected patients. herein present results 1. Methods: Based on Stupp regimen, two sequential dose escalations were performed distinguish radiotherapy period maintenance for...
<p>A. Progression-free (left) and overall (right) survival among the 30 patients enrolled in two sequential olaparib dose-escalations of trial.</p>
<p>C. Progression-free (left) and overall (right) survival for first second olaparib dose-escalation cohorts of the trial. was defined as time elapsed from treatment start to RANO progression or death any cause (whichever occurs first); Overall cause.</p>
<p>B. Progression-free (left) and overall (right) survival according to MGMT status among the patients enrolled in two sequential olaparib dose-escalations of trial.</p>
<p>Magnetic Resonance Imaging (gadolinium, FLAIR and perfusion sequences from left to right) at baseline (top) 60 months (bottom) after start of treatment in first line a partially resected glioblastoma patient.</p>
<div>AbstractPurpose:<p>Radiochemotherapy remains the mainstay of glioblastoma (GBM) first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve GBM outcomes. We implemented a phase I to IIa trial assess safety and efficacy combined with standard radiochemotherapy as in patients unresected GBM. herein present results I.</p>Patients Methods:<p>Based on Stupp regimen, two sequential dose escalations were performed...
Leiomyosarcoma (LMS) are 15% of adult sarcomas and remain seldom curable in metastatic phase. The TAM receptors their ligands overexpressed or activated multiple malignancies, including LMS.The receptor ligand expression was evaluated LMS cell lines 358 sarcoma samples by either gene immunohistochemistry. TYRO3 AXL were knocked down. Crizotinib foretinib investigated vitro.High detected lines. knockdown reduced proliferation/colony formation. decreased phosphorylation, apoptosis, G2/arrest...
A series of 42 patient tumors diagnosed as endometrial stromal sarcoma (ESS) based on the morphology but negative for JAZF1 and/or YWHAE rearrangement in FISH was analyzed by RNA-sequencing. chromosomal identified 31 (74%) cases and a missense mutation known oncogenes/tumor suppressor genes 11 (26%). Cluster analyses expression profiles from this together with control cohort composed five samples low grade ESS harboring JAZF1-SUZ12 fusion, one high BCOR-ITD, two uterine resembling ovarian...